viewSynovis Life Technologies, Inc.

Synovis Life beats Street for Q3


Medical device maker Synovis Life Technologies (NASDAQ:SYNO) said fiscal third-quarter revenue spiked 19%, while profits rose 33%, beating analyst estimates.

The company, which makes products to repair and reconstruct skin tissue, managed to grow revenue in the double digits for the 17th consecutive quarter, amid a challenging economic climate for the healthcare industry.

Net sales grew to a record $21 million for the three months ending July 31. That compares with $17.6 million, a year ago.

"Our strong portfolio of soft tissue repair products has proven again that it is a powerful generator of revenue growth and profitability," said president and CEO, Richard Kramp.

The company reported profits of $2 million, or 17 cents per fully diluted share, compared to $1.5 million, or 13 cents per fully diluted share, a year earlier.

Analysts expected earnings of around 15 cents a share, on revenue of $20.5 million.

Operating income for the third quarter grew 32% to $3.0 million, while gross margin came in flat at 72.4%.

For the quarter, revenue for Peri-StripsDry, which is a biomaterial used to reduce fatal leaks in gastric bypass surgery, rose 20% to $6 million.

"The number of gastric sleeve procedures performed is on the rise as private insurance companies increasingly reimburse for this cost-effective surgery,” said Synovis in a statement.

Revenue from Veritas, a collagen-based material sold for ventral hernia and breast reconstruction, jumped 7%, while sales from tissue guard products grew 12% as the company sold more units at higher prices.

Sales from Synovis’ microsurgical product business shot up 45% year-over-year, driven by strong demand for Deep Inferior Epigastric Perforator Flap Procedure (DIEP) breast reduction procedures.

The company's orthopaedic and wound product division saw revenue climb 36%, with collagen-based Unite Biomatrix – which is used to treat chronic wounds – fueling the growth.

On the cost side, selling, general and administrative expenses grew 16% to $11 million, stemming from investments in sales and marketing, personnel expenses, as well as initiatives to grow revenue.

The St. Paul, Minnesota-based company’s shares climbed 18 cents, or 1.14%, to $15.93 Wednesday on the Nasdaq.

Quick facts: Synovis Life Technologies, Inc.

Price: - -

Market: NASDAQ
Market Cap: -

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...


Orthocell 'in exciting regulatory phase' as it looks to drive its...

Orthocell Ltd's (ASX:OCC) Paul Anderson says the company's in an exciting regulatory phase having validated its technologies in the clinic and defining pathways to market through the US FDA process. ''We have some significant milestones ahead of us - we have an application within the FDA at the...

18 hours, 30 minutes ago

2 min read